• HyperFluor™ 594 Goat Anti-Rabbit IgG: Specificity & Protocol

  2026-05-13

  The HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody is an affinity-purified, fluorophore-conjugated secondary antibody from APExBIO. It enables sensitive, multiplexed detection of rabbit IgG in immunocytochemistry, IHC, and flow cytometry, with strict protocol parameters for optimal signal and specificity. This dossier details its mechanism, benchmarks, and practical integration in advanced research workflows.

• EPZ5676: Transforming DOT1L Inhibitor Workflows in Leukemia

  2026-05-13

  EPZ5676, a highly selective DOT1L inhibitor, empowers researchers to dissect H3K79 methylation with unmatched precision. This guide delivers practical workflow strategies, troubleshooting insights, and comparative advantages for MLL-rearranged leukemia studies.

• DiscoveryProbe™ Metabolism-related Compound Library: Technic

  2026-05-12

  The DiscoveryProbe™ Metabolism-related Compound Library provides researchers with a rigorously validated, ready-to-use collection of 493 metabolism-related small molecules, streamlining high-throughput metabolic enzyme assays and pathway studies. It is designed for in vitro and ex vivo research only and should not be used for diagnostic or clinical applications.

• IBDV VP3 Protein Suppresses IRF7 to Enhance Viral Replicatio

  2026-05-12

  This study reveals that infectious bursal disease virus (IBDV) exploits its VP3 protein to degrade interferon regulatory factor 7 (IRF7) and suppress type I interferon responses in chicken cells. These findings uncover a novel viral evasion mechanism, with implications for controlling immunosuppressive diseases in poultry.

• Bazedoxifene: Applied SERM Workflows for Osteoporosis Resear

  2026-05-11

  Bazedoxifene empowers researchers to dissect estrogen receptor signaling and bone mineral density enhancement with unmatched tissue selectivity. Explore optimized experimental protocols, comparative advantages, and troubleshooting tips for robust postmenopausal osteoporosis models.

• Nerve-Controlled HDAC1 Expression Drives Axolotl Limb Regene

  2026-05-11

  This study reveals that nerve-mediated upregulation of histone deacetylase 1 (HDAC1) is essential for blastema formation and successful limb regeneration in axolotls. Pharmacological inhibition of HDACs, including with TSA, disrupts this process, highlighting critical epigenetic regulation linking nerve signaling and regenerative capacity.

• G418 Sulfate: Precision Selection Meets Antiviral Innovation

  2026-05-10

  Explore how Geneticin (G-418 Sulfate) transcends its legacy as a genetic engineering selection antibiotic, offering not only robust neomycin resistance screening but also promising antiviral activity—particularly against Dengue virus serotype 2. This article integrates mechanistic insights, state-of-the-art protocol guidance, and translational strategies, positioning APExBIO’s Geneticin as a pivotal tool for next-generation biomedical research.

• M344: Potent Histone Deacetylase Inhibitor for Cancer Resear

  2026-05-09

  M344 is a cell-permeable histone deacetylase inhibitor used to modulate gene expression and induce cell differentiation in cancer and HIV-1 latency models. It displays nanomolar IC50 potency and robustly inhibits breast cancer, medulloblastoma, and neuroblastoma cell proliferation. Evidence supports its role as an advanced tool for epigenetic research and workflow integration.

• E. coli Uracil-DNA Glycosylase (UDG): Technical Lab Guidance

  2026-05-08

  E. coli Uracil-DNA Glycosylase (UDG) is designed for the precise removal of uracil residues from DNA, supporting PCR contamination control and DNA repair workflows. It is not suitable for RNA, oligonucleotides shorter than six bases, or any diagnostic or clinical use. Researchers should apply it strictly within scientific research protocols where uracil excision from DNA is required.

• Primidone (Mysoline): Protocols and Innovations for TRPM3 &

  2026-05-08

  Primidone (Mysoline) offers unique selectivity as both a TRPM3 and RIPK1 inhibitor, enabling translational research in neurodevelopmental and neurodegenerative models. Explore optimized workflows, troubleshooting strategies, and data-driven dosing for reliable in vitro and in vivo outcomes.

• GSK126 EZH2 Inhibitor: Transforming Cancer Epigenetics Workf

  2026-05-07

  GSK126, a highly selective EZH2 inhibitor, empowers researchers to dissect PRC2-dependent gene silencing in cancer and stem cell models with unmatched precision. Its proven ability to enable self-renewal in naive pluripotent stem cells and enhance sensitivity to chemotherapeutics makes it indispensable for cutting-edge oncology and epigenetics research.

• GSK343: Advanced EZH2 Inhibitor Workflows for Epigenetic Res

  2026-05-07

  GSK343, a potent and selective EZH2 inhibitor from APExBIO, empowers researchers to precisely dissect PRC2-mediated gene repression and chromatin regulation in cancer and stem cell models. This article details optimized experimental workflows, advanced troubleshooting, and protocol parameters that leverage GSK343 for robust inhibition of histone H3K27 trimethylation, with actionable insights drawn from the latest discoveries in telomerase gene regulation.

• TRIM21 Drives ERK1/2 Activation and Drug Resistance in Pitui

  2026-05-06

  This study provides compelling evidence that TRIM21 promotes cell proliferation and dopamine agonist resistance in pituitary adenomas by modulating ERK1/2 ubiquitination and phosphorylation. Importantly, it identifies Quisinostat as a pharmacological agent capable of downregulating TRIM21, highlighting a potential therapeutic strategy for drug-resistant pituitary tumors.

• Gingerenone A Reverses Sunitinib Resistance via LDHA Inhibit

  2026-05-06

  This study identifies gingerenone A as a potent inhibitor of LDHA-mediated glycolysis in renal cell carcinoma (RCC), restoring sensitivity to sunitinib in resistant tumor models. By directly targeting metabolic reprogramming, gingerenone A offers a promising approach to overcoming tyrosine kinase inhibitor resistance in RCC.

• GSK126 EZH2 Inhibitor: Precision Targeting of Oncogenic Epig

  2026-05-05

  Explore the advanced applications of GSK126, a potent EZH2 inhibitor, in cancer epigenetics research. This article uniquely examines the mechanistic interplay between ETV5, EZH2, and tumor progression, offering actionable insights for oncology drug development.

15733 records 1/1049 page Next 12345 下5页 Last page